DFDA

Liraglutide

Treatment for Chronic Kidney Disease Due To Diabetes Mellitus Type 1

Typical Dosage: 0.6-1.8mg subcutaneous injection daily

Effectiveness
75%
Safety Score
60%
Clinical Trials
100
Participants
50K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
0.6-1.8mg subcutaneous injection daily
Time to Effect
Weeks for glycemic control, months to years for CV/weight effects
Treatment Duration
Lifetime
Evidence Quality
MODERATE
Number Needed to Harm (NNH)
10(Treat 10 patients to see 1 additional serious adverse event)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$10,000
Monitoring:$100
Side Effect Mgmt:$100
Total Annual:$10,200
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATE
ICER
$100,000/QALY
QALYs Gained
0.4
Outcome-Based Costs
Cost per Responder
$15,692
Liraglutide Outcomes

for Chronic Kidney Disease Due To Diabetes Mellitus Type 1

Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+65%
Common Side Effects
Nausea
+25%
Diarrhea
+12%
Vomiting
+7%
Pancreatitis
+0.1%

Sources:

nih.gov
nih.gov
researchgate.net

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov